Professor Michael Boyer AM
Michael Boyer is a medical oncologist at Chris O’Brien Lifehouse, where he also holds the position of Chief Clinical Officer. He also holds the Kam Ling Barbara Lo Chair in Lung and Thoracic Cancer
at the Central Clinical School, University of Sydney.
Following his specialty training in medical oncology at Royal Prince Alfred and Westmead Hospitals, in Sydney, Professor Boyer was a Research Fellow and Clinical Fellow at the Ontario Cancer Institute and Princess Margaret Hospital in Toronto, Canada, where he completed his PhD in cell biology. He was on the senior staff of the Sydney Cancer Centre and Royal Prince Alfred Hospital from 1993 to 2013. He played an integral role in the development and construction of the Chris O’Brien Lifehouse, a purpose-built cancer hospital, and joined the staff on its opening in 2013. In addition to his clinical roles, he has held senior administrative positions during that time including Head of Department of Medical Oncology at Royal Prince Alfred Hospital, Director of the Sydney Cancer Centre, and Area Director of Cancer Services for the Sydney South West Area Health Service. In 2010 he was made a Member of the Order of Australia for his work as an educator, a clinical trials researcher and for his involvement in the development of integrated care facilities for people suffering with cancer.
Professor Boyer has 30 years of experience in the management of thoracic malignancies and head and neck cancers. His major research interest is in clinical trials of new agents in the management of lung cancer, mesothelioma and head and neck cancers. He is the author of over 180 publications, has given numerous national and international presentations, both invited and selected from abstract submission, and is actively involved in the lung cancer community. He chaired the scientific advisory committee of the Australasian Lung Cancer Trials Group between 2004 and 2011 and was the conference Co-President for the 15th World Conference on Lung Cancer held in Sydney in 2013. He was a member of the Board of Directors of the International Association for the Study of Lung Cancer from 2009 – 2013 and again from 2015 to 2019. He was Director of the Sydney Catalyst Translational Cancer Research Centre from 2017 – 2021. He is currently a member of the Cancer Australia Lung Cancer Advisory Group and is a Board member of the Thoracic Oncology Group of Australasia.